Current Osteoporosis Reports

, Volume 14, Issue 2, pp 54–65 | Cite as

Osteoporosis Associated with Epilepsy and the Use of Anti-Epileptics—a Review

  • Sandra J. PettyEmail author
  • Helen Wilding
  • John D. Wark
Secondary Causes of Osteoporosis (SJ Warden, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Secondary Causes of Osteoporosis


The increased rate of fractures associated with epilepsy has been long recognised but remains incompletely understood. Study quality and study results have varied, with some but not all studies showing bone diseases including osteoporosis and/or osteomalacia, and a high prevalence of vitamin D insufficiency and deficiency are also noted. Falls risk can also be higher in patients with epilepsy taking anti-epileptic medications, potentially leading to fracture. Larger research collaborations are recommended to further advance understanding in this field, particularly to examine underlying genetic and pharmacogenomic associations of epilepsy and anti-epileptic medication usage and its association with bone diseases and fractures, as well as further investigation into optimal management of bone health in epilepsy.


Epilepsy Anti-epileptic medication Osteoporosis Fracture risk 


Compliance with Ethical Standards

Conflict of Interest

Helen Wilding declares no conflict of interest. Sandra J. Petty reports grants from UCB Pharma, grants from Novartis, other from UCB Pharma, outside the submitted work. John D. Wark reports grants from UCB Pharma, grants from Novartis, outside the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with animal subjects performed by any of the authors. All studies performed by the authors’ references in this paper were approved by the relevant institutional human research ethics committee.


Papers of particular interest, published recently, have been highlighted as: • Of importance, •• Of major importance

  1. 1.
    Kruse R. Osteopathies, calcium- and vitamin D metabolism errors during anti-epileptic long term therapy. Bibl Psychiatr. 1975;151:114–43.PubMedGoogle Scholar
  2. 2.
    Shen C, Chen F, Zhang Y, Guo Y, Ding M. Association between use of antiepileptic drugs and fracture risk: a systematic review and meta-analysis. Bone. 2014;64:246–53. doi: 10.1016/j.bone.2014.04.018.PubMedCrossRefGoogle Scholar
  3. 3.
    Ali II, Schuh L, Barkley GL, Gates JR. Antiepileptic drugs and reduced bone mineral density. Epilepsy and Behavior. 2004;5(3):296–300.PubMedCrossRefGoogle Scholar
  4. 4.
    Fife TD, Blum D, Fisher RS. Measuring the effects of antiepileptic medications on balance in older people. Epilepsy Res. 2006;70(2–3):103–9. doi: 10.1016/j.eplepsyres.2006.03.004.PubMedCrossRefGoogle Scholar
  5. 5.
    WHO Study Group, Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporosis International. 1994;4(6):368–81.CrossRefGoogle Scholar
  6. 6.
    Kanis JA, McCloskey EV, Johansson H, Oden A, Melton 3rd LJ, Khaltaev N. A reference standard for the description of osteoporosis. Bone. 2008;42(3):467–75. doi: 10.1016/j.bone.2007.11.001.PubMedCrossRefGoogle Scholar
  7. 7.
    Elliott ME, Binkley N. Evaluation and measurement of bone mass. Epilepsy & Behavior. 2004;5(Suppl2):S16–23. doi: 10.1016/j.yebeh.2003.11.027.CrossRefGoogle Scholar
  8. 8.
    Kanis J. Assessment of osteoporosis at the primary health care level. Sheffield: World Health Organization; 2007.Google Scholar
  9. 9.
    Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1–129.Google Scholar
  10. 10.
    Salimipour H, Kazerooni S, Seyedabadi M, Nabipour I, Nemati R, Iranpour D, et al. Antiepileptic treatment is associated with bone loss: difference in drug type and region of interest. Journal of Nuclear Medicine Technology. 2013;41(3):208–11.PubMedCrossRefGoogle Scholar
  11. 11.
    Pickrell WO, Lacey AS, White CP, Rees MI, Natarajan J. Fractures in people with a diagnosis of epilepsy: a population based study. Epilepsia2014. 29–30.Google Scholar
  12. 12.
    Mintzer S. Metabolic consequences of antiepileptic drugs. Curr Opin Neurol. 2010;23(2):164–9. doi: 10.1097/WCO.0b013e32833735e7.PubMedCrossRefGoogle Scholar
  13. 13.
    Arora SK, Bubb C, Karam J, McFarlane SI. Expanding use of anti-epileptic therapy: implications on bone disease. Therapy. 2007;4(1):79–89.CrossRefGoogle Scholar
  14. 14.
    Beerhorst K, van der Kruijs SJ, Verschuure P, Tan IY, Aldenkamp AP. Bone disease during chronic antiepileptic drug therapy: general versus specific risk factors. Journal of the Neurological Sciences. 2013;331(1–2):19–25. doi: 10.1016/j.jns.2013.05.005.PubMedCrossRefGoogle Scholar
  15. 15.
    Gissel T, Poulsen CS, Vestergaard P. Adverse effects of antiepileptic drugs on bone mineral density in children. Expert Opin Drug Saf. 2007;6(3):267–78.PubMedCrossRefGoogle Scholar
  16. 16.
    Hahn TJ. Bone complications of anticonvulsants. Drugs. 1976;12(3):201–11.PubMedCrossRefGoogle Scholar
  17. 17.
    Svalheim S, Roste LS, Nakken KO, Tauboll E. Bone health in adults with epilepsy. Acta Neurologica Scandinavica. 2011;191:89–95. doi: 10.1111/j.1600-0404.2011.01551.x.PubMedCrossRefGoogle Scholar
  18. 18.
    Khanna S, Pillai KK, Vohora D. Insights into liaison between antiepileptic drugs and bone. Drug Discov Today. 2009;14(7–8):428–35. doi: 10.1016/j.drudis.2009.01.004.PubMedCrossRefGoogle Scholar
  19. 19.
    Miziak B, Blaszczyk B, Chroscinska-Krawczyk M, Danilkiewicz G, Jagiello-Wojtowicz E, Czuczwar SJ. The problem of osteoporosis in epileptic patients taking antiepileptic drugs. Expert Opin Drug Saf. 2014;13(7):935–46. doi: 10.1517/14740338.2014.919255.PubMedCrossRefGoogle Scholar
  20. 20.
    Samaniego EA, Sheth RD. Bone consequences of epilepsy and antiepileptic medications. Semin Pediatr Neurol. 2007;14(4):196–200.PubMedCrossRefGoogle Scholar
  21. 21.
    Verrotti A, Coppola G, Parisi P, Mohn A, Chiarelli F. Bone and calcium metabolism and antiepileptic drugs. Clin Neurol Neurosurg. 2010;112(1):1–10. doi: 10.1016/j.clineuro.2009.10.011.PubMedCrossRefGoogle Scholar
  22. 22.
    Fitzpatrick LA. Pathophysiology of bone loss in patients receiving anticonvulsant therapy. Epilepsy & behavior : E&B. 2004;5 Suppl 2:S3–15. doi: 10.1016/j.yebeh.2003.11.026.CrossRefGoogle Scholar
  23. 23.
    Petty SJ, Hill KD, Haber NE, Paton LM, Lawrence KM, Berkovic SF, et al. Balance impairment in chronic antiepileptic drug users: a twin and sibling study. Epilepsia. 2010;51(2):280–8. doi: 10.1111/j.1528-1167.2009.02254.x.PubMedCrossRefGoogle Scholar
  24. 24.•
    Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia. 2013;54(1):11–27. doi: 10.1111/j.1528-1167.2012.03671.x. An important review for neurologists and prescribers of enzyme-inducing AEMs and the multiple associated comorbidities.PubMedCrossRefGoogle Scholar
  25. 25.
    Vestergaard P, Tigaran S, Rejnmark L, Tigaran C, Dam M, Mosekilde L. Fracture risk is increased in epilepsy. Acta neurologica Scandinavica 1999.Google Scholar
  26. 26.
    Latorre H, Kenny FM. High dosage intravenous calcium therapy for osteoporosis and osteomalacia in anticonvulsant therapy with hypomobilization. Pediatrics. 1974;53(1):100–5.PubMedGoogle Scholar
  27. 27.
    Lidgren L, Nilsson BE, Walloe A. Bone mineral content in epileptics. Calcified Tissue International. 1979;28(2):99–102.PubMedCrossRefGoogle Scholar
  28. 28.
    Nilsson OS, Lindholm TS, Elmstedt E, Lindback A, Lindholm TC. Fracture incidence and bone disease in epileptics receiving long-term anticonvulsant drug treatment. Arch Orthop Trauma Surg. 1986;105(3):146–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Murchison LE, Bewsher PD, Chesters M. Effects of anticonvulsants and inactivity on bone disease in epileptics. Postgraduate Medical Journal. 1975;51(1):18–21.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Weinstein RS, Bryce GF, Sappington LJ. Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment. Journal of Clinical Endocrinology and Metabolism. 1984;58(6):1003–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Petty S. Epilepsy and bone health. Neurology Asia. 2011;16(1):63–4.Google Scholar
  32. 32.
    Valmadrid C, Voorhees C, Litt B, Schneyer CR. Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy. Arch Neurol. 2001;58(9):1369–74.PubMedCrossRefGoogle Scholar
  33. 33.
    Ahmad BS, Hill KD, O’Brien TJ, Gorelik A, Habib N, Wark JD. Falls and fractures in patients chronically treated with antiepileptic drugs. Neurology. 2012;79(2):145–51.CrossRefGoogle Scholar
  34. 34.
    Souverein P, Webb D, Weil J, Van Staa T, Egberts A. Use of antiepileptic drugs and risk of fractures: case–control study among patients with epilepsy. Neurology. 2006;66(9):1318–24. doi: 10.1212/01.wnl.0000210503.89488.88.PubMedCrossRefGoogle Scholar
  35. 35.
    Stephen LJ, McLellan AR, Harrison JH, Shapiro D, Dominiczak MH, Sills GJ, et al. Bone density and antiepileptic drugs: a case-controlled study. Seizure. 1999;8(6):339–42.PubMedCrossRefGoogle Scholar
  36. 36.
    Wark JD, Larkins RG, Perry-Keene D, Peter CT, Ross DL, Sloman JG. Chronic diphenylhydantoin therapy does not reduce plasma 25-hydroxy-vitamin D. Clin Endocrinol (Oxf). 1979;11(3):267–74.CrossRefGoogle Scholar
  37. 37.
    Sato Y, Kondo I, Ishida S, Motooka H, Takayama K, Tomita Y, et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology. 2001;57(3):445–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Sheth RD, Wesolowski CA, Jacob JC, Penney S, Hobbs GR, Riggs JE, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr. 1995;127(2):256–62.PubMedCrossRefGoogle Scholar
  39. 39.
    Cheah J, Stacpoole S, Heaney D, Duncan J. Are we measuring the bone health of epilepsy patients? Rheumatology. 2010;49:i84.Google Scholar
  40. 40.
    Adler R, Semla T, Cunningham F, Pogach L. Potential under-treatment of male veterans with or at risk for osteoporotic fractures. J Bone Mineral Res 2010. S473.Google Scholar
  41. 41.
    Tohill C. A study into the possible link between anti-epileptic drugs and the risk of fractures in Muckamore Abbey Hospital. Journal of Intellectual and Developmental Disability. 1997;22(4):281–92. doi: 10.1080/13668259700033501.CrossRefGoogle Scholar
  42. 42.
    Lyngstad-Brechan MA, Tauboll E, Nakken KO, Gjerstad L, Godang K, Jemtland R, et al. Reduced bone mass and increased bone turnover in postmenopausal women with epilepsy using antiepileptic drug monotherapy. Scand J Clin Lab Invest. 2008;68(8):759–66. doi: 10.1080/00365510802233442.PubMedCrossRefGoogle Scholar
  43. 43.
    Beerhorst K, Tan IY, De Krom M, Verschuure P, Aldenkamp AP. Antiepileptic drugs and high prevalence of low bone mineral density in a group of inpatients with chronic epilepsy. Acta Neurologica Scandinavica. 2013;128(4):273–80. doi: 10.1111/ane.12118.PubMedCrossRefGoogle Scholar
  44. 44.
    Beerhorst K, Tan J, Tan IY, Verschuure P, Aldenkamp AP. Dual-energy X-ray absorptiometry versus quantitative ultrasonography in diagnosing osteoporosis in patients with refractory epilepsy and chronic antiepileptic drug use. Ther. 2013;5(2):59–66. doi: 10.1177/1759720X13475851.Google Scholar
  45. 45.
    Vestergaard P. Changes in bone turnover, bone mineral and fracture risk induced by drugs used to treat epilepsy. Curr Drug Saf. 2008;3(3):168–72.PubMedCrossRefGoogle Scholar
  46. 46.
    Roohi F, Fox A. Burst fracture of the first lumbar vertebra and conus-cauda syndrome complicating a single convulsive seizure: a challenge of diagnosis in the emergency department. Journal of Emergency Medicine. 2006;31(4):381–5.PubMedCrossRefGoogle Scholar
  47. 47.
    Napier R, Nolan PC. Diagnosis of vertebral fractures in post-ictal patients. Emergency Medicine Journal. 2011;28(2):169–70.PubMedCrossRefGoogle Scholar
  48. 48.
    Copuroglu C, Ozcan M, Dulger H, Yalniz E. Late-diagnosed bilateral intertrochanteric femur fracture during an epileptic seizure. Ulus Travma Acil Cerrahi Derg. 2012;18(1):92–4. doi: 10.5505/tjtes.2011.76402.PubMedCrossRefGoogle Scholar
  49. 49.
    Alenazi B, Rana AQ, Vaid HM. The importance of imaging for status epilepticus patients to rule out fractures—a case report. Journal of Taibah University Medical Sciences. 2013;8(2):120–2.CrossRefGoogle Scholar
  50. 50.
    Caffarelli C, Hayek J, Tomai Pitinca MD, Nuti R, Gonnelli S. A comparative study of dual-X-ray absorptiometry and quantitative ultrasonography for the evaluating bone status in subjects with Rett syndrome. Calcified Tissue International. 2014;95(3):248–56. doi: 10.1007/s00223-014-9888-x.PubMedCrossRefGoogle Scholar
  51. 51.
    Reyes C, Formiga F, Coderch M, Hoyo J, Ferriz G, Casanovas J, et al. Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region. Bone. 2013;52(2):557–61. doi: 10.1016/j.bone.2012.09.028.PubMedCrossRefGoogle Scholar
  52. 52.
    Kanis J, Johnell O, Gullberg B, Allander E, Elffors L, Ranstam J, et al. Risk factors for hip fracture in men from southern Europe: the MEDOS study. Mediterranean Osteoporosis Study. Osteoporosis International. 1999;9(1):45–54.PubMedCrossRefGoogle Scholar
  53. 53.
    Nicholas JM, Ridsdale L, Richardson MP, Grieve AP, Gulliford MC. Fracture risk with use of liver enzyme inducing antiepileptic drugs in people with active epilepsy: cohort study using the general practice research database. Seizure. 2013;22(1):37–42. doi: 10.1016/j.seizure.2012.10.002.PubMedCrossRefGoogle Scholar
  54. 54.
    Abrahamsen B, Brixen K. Mapping the prescriptiome to fractures in men—a national analysis of prescription history and fracture risk. Osteoporosis International. 2009;20(4):585–97. doi: 10.1007/s00198-008-0711-2.PubMedCrossRefGoogle Scholar
  55. 55.
    Annegers JF, Melton 3rd LJ, Sun CA, Hauser WA. Risk of age-related fractures in patients with unprovoked seizures. Epilepsia. 1989;30(3):348–55.PubMedCrossRefGoogle Scholar
  56. 56.
    Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995;332(12):767–73. doi: 10.1056/NEJM199503233321202.PubMedCrossRefGoogle Scholar
  57. 57.
    Persson HB, Alberts KA, Farahmand BY, Tomson T. Risk of extremity fractures in adult outpatients with epilepsy. Epilepsia. 2002;43(7):768–72.PubMedCrossRefGoogle Scholar
  58. 58.
    Lapi F, Simonetti M, Michieli R, Pasqua A, Brandi ML, Frediani B, et al. Assessing 5-year incidence rates and determinants of osteoporotic fractures in primary care. Bone. 2012;50(1):85–90. doi: 10.1016/j.bone.2011.09.048.PubMedCrossRefGoogle Scholar
  59. 59.
    Tsiropoulos I, Andersen M, Nymark T, Lauritsen J, Gaist D, Hallas J. Exposure to antiepileptic drugs and the risk of hip fracture: a case–control study. Epilepsia. 2008;49(12):2092–9. doi: 10.1111/j.1528-1167.2008.01640.x.PubMedCrossRefGoogle Scholar
  60. 60.•
    Beerhorst K, Schouwenaars FM, Tan IY, Aldenkamp AP. Epilepsy: fractures and the role of cumulative antiepileptic drug load. Acta Neurologica Scandinavica. 2012;125(1):54–9. doi: 10.1111/j.1600-0404.2011.01509.x. Introduces the concept of cumulative AEM load and effects on bone health.PubMedCrossRefGoogle Scholar
  61. 61.
    Petty SJ, Paton LM, O’Brien TJ, Makovey J, Erbas B, Sambrook P, et al. Effect of antiepileptic medication on bone mineral measures. Neurology. 2005;65(9):1358–63.PubMedCrossRefGoogle Scholar
  62. 62.
    Badcock LJ, Smith JA, Price T, Mulherin DM. Bone mineral density in post-menopausal women on anticonvulsant therapy. Journal of the Irish Colleges of Physicians and Surgeons. 2000;29(3):138–40.Google Scholar
  63. 63.
    Petty SJ, O’Brien TJ, Wark JD. Anti-epileptic medication and bone health. Osteoporosis International. 2007;18(2):129–42.PubMedCrossRefGoogle Scholar
  64. 64.
    Moro-Alvarez MJ, Diaz Curiel M, de la Piedra C, Marinoso ML, Carrascal MT. Bone disease induced by phenytoin therapy: clinical and experimental study. Eur Neurol. 2009;62(4):219–30. doi: 10.1159/000229309.PubMedCrossRefGoogle Scholar
  65. 65.••
    Pack AM. Genetic variation may clarify the relationship between epilepsy, antiepileptic drugs, and bone health. European Journal of Neurology. 2011;18(1):3–4. doi: 10.1111/j.1468-1331.2010.03137.x. A review of new studies examining vitamin D receptor genetic variation and the association between epilepsy and bone health.PubMedCrossRefGoogle Scholar
  66. 66.
    Hamed SA, Moussa EM, Youssef AH, Abd ElHameed MA, NasrEldin E. Bone status in patients with epilepsy: relationship to markers of bone remodeling. Front Neurol. 2014;5:142. doi: 10.3389/fneur.2014.00142.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Farhat G, Yamout B, Mikati MA, Demirjian S, Sawaya R, El-Hajj FG. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology. 2002;58(9):1348–53.PubMedCrossRefGoogle Scholar
  68. 68.
    Mattson RH, Gidal BE. Fractures, epilepsy, and antiepileptic drugs. Epilepsy & Behavior. 2004;5 Suppl 2:S36–40.CrossRefGoogle Scholar
  69. 69.
    Lee R, Lyles K, Sloane R, Colon-Emeric C. The association between newer anticonvulsants and bone mineral density. J Bone Mineral Res 2011.Google Scholar
  70. 70.
    Koo DL, Joo EY, Kim D, Hong SB. Effects of levetiracetam as a monotherapy on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy. Epilepsy Res. 2013;104(1–2):134–9. doi: 10.1016/j.eplepsyres.2012.09.002.PubMedCrossRefGoogle Scholar
  71. 71.
    Ensrud KE, Walczak TS, Blackwell TL, Ensrud ER, Barrett-Connor E, Orwoll ES, et al. Antiepileptic drug use and rates of hip bone loss in older men: a prospective study. Neurology. 2008;71(10):723–30. doi: 10.1212/01.wnl.0000324919.86696.a9.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Meier C, Kraenzlin ME. Antiepileptics and bone health. Ther. 2011;3(5):235–43. doi: 10.1177/1759720X11410769.Google Scholar
  73. 73.
    Pack AM, Morrell MJ, Randall A, McMahon DJ, Shane E. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology. 2008;70(18):1586–93. 8p.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Guo CY, Ronen GM, Atkinson SA. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia. 2001;42(9):1141–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Akin RI, Okutan V, Sarici U, Altunbaş A, Gökçay E. Evaluation of bone mineral density in children receiving antiepileptic drugs. Pediatric Neurology. 1998;19(2):129–31.PubMedCrossRefGoogle Scholar
  76. 76.
    Chou IJ, Lin KL, Wang HS, Wang CJ. Evaluation of bone mineral density in children receiving carbamazepine or valproate monotherapy. Acta Paediatr Taiwan. 2007;48(6):317–22.PubMedGoogle Scholar
  77. 77.
    Baek JH, Seo YH, Kim GH, Kim MK, Eun BL. Vitamin D levels in children and adolescents with antiepileptic drug treatment. Yonsei Med J. 2014;55(2):417–21. doi: 10.3349/ymj.2014.55.2.417.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Gniatkowska-Nowakowska A. Fractures in epilepsy children. Seizure. 2010;19(6):324–5. doi: 10.1016/j.seizure.2010.04.013.PubMedCrossRefGoogle Scholar
  79. 79.
    Mirza N, Marson AG, Pirmohamed M. Effect of topiramate on acid–base balance: extent, mechanism and effects. Br J Clin Pharmacol. 2009;68(5):655–61. doi: 10.1111/j.1365-2125.2009.03521.x.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Bergqvist AG, Schall JI, Stallings VA, Zemel BS. Progressive bone mineral content loss in children with intractable epilepsy treated with the ketogenic diet. Am J Clin Nutr. 2008;88(6):1678–84. doi: 10.3945/ajcn.2008.26099.PubMedCrossRefGoogle Scholar
  81. 81.
    Groesbeck DK, Bluml RM, Kossoff EH. Long-term use of the ketogenic diet in the treatment of epilepsy. Developmental Medicine and Child Neurology. 2006;48(12):978–81.PubMedCrossRefGoogle Scholar
  82. 82.
    Andress DL, Ozuna J, Tirschwell D, Grande L, Johnson M, Jacobson AF, et al. Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol. 2002;59(5):781–6.PubMedCrossRefGoogle Scholar
  83. 83.
    McGrother CW, Donaldson MM, Clayton D, Abrams KR, Clarke M. Evaluation of a hip fracture risk score for assessing elderly women: the Melton Osteoporotic Fracture (MOF) study. Osteoporosis International. 2002;13(1):89–96. doi: 10.1007/s198-002-8343-6.PubMedCrossRefGoogle Scholar
  84. 84.
    Broulik P, Kragstrup J, Mosekilde L, Melsen F. Osteon cross-sectional size in the iliac crest: variation in normals and patients with osteoporosis, hyperparathyroidism, acromegaly, hypothyroidism and treated epilepsia. Acta Pathol Microbiol Immunol Scand [A]. 1982;90(5):339–44.Google Scholar
  85. 85.
    Boluk A, Guzelipek M, Savli H, Temel I, Ozisik HI, Kaygusuz A. The effect of valproate on bone mineral density in adult epileptic patients. Pharmacol Res. 2004;50(1):93–7.PubMedCrossRefGoogle Scholar
  86. 86.
    Bostancioǧlu M, Öner N, Küçükuǧurluoǧlu Y, Kaya M, Aladaǧ N, Çeltik C, et al. Does valproate therapy decrease the bone mineral density in one-year follow-up in children? Trakya Universitesi Tip Fakultesi Dergisi. 2009;26(1):24–8.Google Scholar
  87. 87.
    Feldkamp J, Becker A, Witte OW, Scharff D, Scherbaum WA. Long-term anticonvulsant therapy leads to low bone mineral density—evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes. 2000;108(1):37–43.PubMedGoogle Scholar
  88. 88.
    Pack AM, Morrell MJ. Epilepsy and bone health in adults. Epilepsy & Behavior. 2004;5 Suppl 2:S24–9.CrossRefGoogle Scholar
  89. 89.
    Fraser LA, Burneo JG, Fraser JA. Enzyme-inducing antiepileptic drugs and fractures in people with epilepsy: a systematic review. Epilepsy Res. 2015;116:59–66. doi: 10.1016/j.eplepsyres.2015.07.003.PubMedCrossRefGoogle Scholar
  90. 90.
    Voudris KA, Attilakos A, Katsarou E, Garoufi A, Dimou S, Skardoutsou A, et al. Early alteration in bone metabolism in epileptic children receiving carbamazepine monotherapy owing to the induction of hepatic drug-metabolizing enzymes. J Child Neurol. 2005;20(6):513–6.PubMedGoogle Scholar
  91. 91.
    Pack A. Bone health in people with epilepsy: is it impaired and what are the risk factors? Seizure. 2008;17(2):181–6. doi: 10.1016/j.seizure.2007.11.020.PubMedCrossRefGoogle Scholar
  92. 92.
    Babacan O, Karaoglu A, Vurucu S, Yesilyurt O, Yesilkaya E, Cayci T et al. May long tem oxcarbazepine therapy be leading to secondary hyperparathyroidism? Eur J Paediatric Neurology 2011. S90.Google Scholar
  93. 93.
    Hamed SA. Influences of bone and mineral metabolism in epilepsy. Expert Opin Drug Saf. 2011;10(2):265–80. doi: 10.1517/14740338.2011.534455.PubMedCrossRefGoogle Scholar
  94. 94.
    Kruse K, Bartels H, Ziegler R, Dreller E, Kracht U. Parathyroid function and serum calcitonin in children receiving anticonvulsant drugs. Eur J Pediatr. 1980;133(2):151–6.PubMedCrossRefGoogle Scholar
  95. 95.
    Verrotti A, Greco R, Latini G, Morgese G, Chiarelli F. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia. 2002;43(12):1488–92.PubMedCrossRefGoogle Scholar
  96. 96.
    Pack AM, Walczak TS. Bone health in women with epilepsy: clinical features and potential mechanisms. Int Rev Neurobiol. 2008;83:305–28. doi: 10.1016/S0074-7742(08)00018-4.PubMedCrossRefGoogle Scholar
  97. 97.
    Pack AM. Antiepileptic drugs and bone disease. Clinical Reviews in Bone and Mineral Metabolism. 2004;2(2):159–65.CrossRefGoogle Scholar
  98. 98.
    Pack AM. The impact of long-term antiepileptic drug use on bone health. Advanced Studies in Medicine. 2005;5(6 C):S567–S71.Google Scholar
  99. 99.
    Kruse K. On the pathogenesis of anticonvulsant-drug-induced alterations of calcium metabolism. Eur J Pediatr. 1982;138(3):202–5.PubMedCrossRefGoogle Scholar
  100. 100.
    Kruse K, Suss A, Busse M, Schneider P. Monomeric serum calcitonin and bone turnover during anticonvulsant treatment and in congenital hypothyroidism. J Pediatr. 1987;111(1):57–63.PubMedCrossRefGoogle Scholar
  101. 101.
    Mosekilde L, Hansen HH, Christensen MS, Lund B, Sorensen OH, Melsen F, et al. Fractional intestinal calcium absorption in epileptics on anticonvulsant therapy. Short-term effect of 1,25-dihydroxycholecalciferol and 25-hydroxycholecalciferol. Acta Med Scand. 1979;205(5):405–9.PubMedGoogle Scholar
  102. 102.
    Elliott JO, Jacobson MP, Haneef Z. Homocysteine and bone loss in epilepsy. Seizure. 2007;16(1):22–34.PubMedCrossRefGoogle Scholar
  103. 103.
    Pascussi JM, Robert A, Nguyen M, Walrant-Debray O, Garabedian M, Martin P, et al. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest. 2005;115(1):177–86. doi: 10.1172/JCI21867.PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Kulak CA, Borba VZ, Bilezikian JP, Silvado CE, Paola L, Boguszewski CL. Bone mineral density and serum levels of 25 OH vitamin D in chronic users of antiepileptic drugs. Arq Neuropsiquiatr. 2004;62(4):940–8.PubMedCrossRefGoogle Scholar
  105. 105.
    Phabphal K, Geater A. The association between BsmI polymorphism and risk factors for atherosclerosis in patients with epilepsy taking valproate. Seizure. 2013;22(9):692–7. doi: 10.1016/j.seizure.2013.05.003.PubMedCrossRefGoogle Scholar
  106. 106.
    Phabphal K, Geater A, Limapichart K, Sathirapanya P, Setthawatcharawanich S, Witeerungrot N, et al. The association between BsmI polymorphism and bone mineral density in young patients with epilepsy who are taking phenytoin. Epilepsia. 2013;54(2):249–55. doi: 10.1111/epi.12049.PubMedCrossRefGoogle Scholar
  107. 107.
    De Miguel-Elízaga I, Martínez-Villanueva M, Villegas-Martínez I, Carrasco-Torres R, Martínez-Ruíz A, Cebreiros-López I, et al. Bone loss associated with use of antiepileptic drugs and genetic predisposition. Clinical Chemistry and Laboratory Medicine. 2015;53:S445.Google Scholar
  108. 108.
    Lambrinoudaki I, Kaparos G, Armeni E, Alexandrou A, Damaskos C, Logothetis E, et al. BsmI vitamin D receptor’s polymorphism and bone mineral density in men and premenopausal women on long-term antiepileptic therapy. European Journal of Neurology. 2011;18(1):93–8. doi: 10.1111/j.1468-1331.2010.03103.x.PubMedCrossRefGoogle Scholar
  109. 109.
    de Abreu DA F, Eyles D, Feron F. Vitamin D, a neuro-immunomodulator: implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinology. 2009;34 Suppl 1:S265–77. doi: 10.1016/j.psyneuen.2009.05.023.CrossRefGoogle Scholar
  110. 110.
    Jiang P, Zhu WY, He X, Tang MM, Dang RL, Li HD, et al. Association between vitamin D receptor gene polymorphisms with childhood temporal lobe epilepsy. Int J Environ Res Public Health. 2015;12(11):13913–22. doi: 10.3390/ijerph121113913.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.••
    Lazzari AA, Dussault PM, Thakore-James M, Gagnon D, Baker E, Davis SA, et al. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy—antiepileptic drug and osteoporosis prevention trial. Epilepsia. 2013. doi: 10.1111/epi.12351. Treatment studies—calcium and vitamin D alone do not appear to prevent fractures compared to bisphosphonate.PubMedGoogle Scholar
  112. 112.••
    Dussault P, Davis Jr S, Lazzari AA. The effect of calcium and vitamin D on bone loss in an epileptic population. Arthritis and rheumatism 2012. p. S842. Treatment studies—calcium and vitamin D alone do not appear to prevent fractures compared to bisphosphonate. Google Scholar
  113. 113.
    Pepe I, Campisi G, Scozzari F, Napoli N, Rini G, Di Fede G. Bone loss caused by anticonvulsants: BMD improvement using strontium ranelate. J Bone Mineral Res 2011.Google Scholar
  114. 114.
    Vestergaard P. Epilepsy, osteoporosis and fracture risk—a meta-analysis. Acta Neurologica Scandinavica. 2005;112(5):277–86.PubMedCrossRefGoogle Scholar
  115. 115.
    Davidson DL, Macdonald S. The costs of trauma caused by seizures: can they be reduced? Seizure. 2002;11(5):344–7.PubMedCrossRefGoogle Scholar
  116. 116.
    Koppel BS, Harden CL, Nikolov BG, Labar DR. An analysis of lifetime fractures in women with epilepsy. Acta Neurologica Scandinavica. 2005;111(4):225–8.PubMedCrossRefGoogle Scholar
  117. 117.
    Elliott JO, Seals BF, Jacobson MP. Osteoprotective knowledge in a multiethnic epilepsy population. J Neurosci Nurs. 2008;40(1):14–24. 39.PubMedCrossRefGoogle Scholar
  118. 118.
    Elliott JO, Seals BF, Jacobson MP. Use of the Precaution Adoption Process Model to examine predictors of osteoprotective behavior in epilepsy. Seizure. 2007;16(5):424–37.PubMedCrossRefGoogle Scholar
  119. 119.
    Elliott JO, Jacobson MP. Bone loss in epilepsy: barriers to prevention, diagnosis, and treatment. Epilepsy & Behavior. 2006;8(1):169–75.CrossRefGoogle Scholar
  120. 120.
    Gross RA, Gidal BE, Pack AM. Patient page. Antiseizure drugs and reduced bone density. Neurology. 2004;62(11):E24–5.PubMedCrossRefGoogle Scholar
  121. 121.
    Nakken KO, Tauboll E. Bone loss associated with use of antiepileptic drugs. Expert Opin Drug Saf. 2010;9(4):561–71. doi: 10.1517/14740331003636475.PubMedCrossRefGoogle Scholar
  122. 122.
    Harijan P, Khan A, Hussain N. Vitamin D deficiency in children with epilepsy: do we need to detect and treat it? Journal of Pediatric Neurosciences. 2013;8(1):5–10. doi: 10.4103/1817-1745.111413.PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Marcuccilli CJ. Vitamin D, deficiency in pediatric epilepsy. Journal of Pediatric Epilepsy. 2013;2(3):199–208.Google Scholar
  124. 124.
    Teagarden DL, Meador KJ, Loring DW. Low vitamin D levels are common in patients with epilepsy. Epilepsy Res. 2014;108(8):1352–6. doi: 10.1016/j.eplepsyres.2014.06.008.PubMedPubMedCentralCrossRefGoogle Scholar
  125. 125.
    Cloyd J, Hauser W, Towne A, Ramsay R, Mattson R, Gilliam F, et al. Epidemiological and medical aspects of epilepsy in the elderly. Epilepsy Res. 2006;68 Suppl 1:S39–48.PubMedCrossRefGoogle Scholar
  126. 126.
    Cohen A, Lancman M, Mogul H, Marks S, Smith K. Strategies to protect bone mass in the older patient with epilepsy. Geriatrics. 1997;52(8):5–8. 81.Google Scholar
  127. 127.
    Ziemba KS, Noe KH. Treatment of epilepsy in postmenopausal women. Aging Health. 2010;6(1):87–96.CrossRefGoogle Scholar
  128. 128.
    Khan SA. Women, epilepsy and anti-epileptic drugs. Neurosciences. 2004;9(2):74–9.PubMedGoogle Scholar
  129. 129.
    Crawford P. Best practice guidelines for the management of women with epilepsy. Epilepsia. 2005;46 Suppl 9:117–24.PubMedCrossRefGoogle Scholar
  130. 130.
    Erel T, Guralp O. Epilepsy and menopause. Arch Gynecol Obstet. 2011;284(3):749–55. doi: 10.1007/s00404-011-1936-4.PubMedCrossRefGoogle Scholar
  131. 131.
    Adis Medical Writers. Be aware of the potential effects of menopause on epilepsy and its treatment. Drugs and Therapy Perspectives. 2015;31(5):161–3.CrossRefGoogle Scholar
  132. 132.
    Homann B, Plaschg A, Grundner M, Haubenhofer A, Griedl T, Ivanic G, et al. The impact of neurological disorders on the risk for falls in the community dwelling elderly: a case-controlled study. BMJ Open. 2013;3(11), e003367. doi: 10.1136/bmjopen-2013-003367.PubMedPubMedCentralCrossRefGoogle Scholar
  133. 133.
    Stolze H, Klebe S, Zechlin C, Baecker C, Friege L, Deuschl G. Falls in frequent neurological diseases—prevalence, risk factors and aetiology. J Neurol. 2004;251(1):79–84. doi: 10.1007/s00415-004-0276-8.PubMedCrossRefGoogle Scholar
  134. 134.
    Lee L, Wagner M, Wu B. Epilepsy patients should receive DXA screening. Epilepsy Currents. 2013;13:92–3.CrossRefGoogle Scholar
  135. 135.
    Drezner MK. Treatment of anticonvulsant drug-induced bone disease. Epilepsy & Behavior. 2004;5 Suppl 2:S41–7.CrossRefGoogle Scholar
  136. 136.
    Kurth C, Keller L, Steinhoff BJ. Determination of alkaline phosphatase without isozymes is not appropriate for monitoring of increased bonemass turnover in patients on inducing antiepileptic drugs. Epilepsia. 2009;50:49.Google Scholar
  137. 137.
    Elliott JO. Possible methods for the prevention of bone loss in persons with epilepsy. Expert rev. 2009;9(6):797–812. doi: 10.1586/ern.09.35.Google Scholar
  138. 138.
    Johnston CA, Crawford PM. Anti-epileptic drugs and hormonal treatments. Current Treatment Options in Neurology. 2014;16(5):288. doi: 10.1007/s11940-014-0288-3.PubMedCrossRefGoogle Scholar
  139. 139.
    Lazzari AA, Dussault P, Davis S. Improvement of treatment decisions in epileptic patients by performing lateral vertebral assessment (LVA). Journal of Clinical Densitometry. 2010;13:118.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Sandra J. Petty
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    Email author
  • Helen Wilding
    • 8
  • John D. Wark
    • 4
    • 9
  1. 1.Melbourne Brain Centre, The Florey Institute of Neuroscience and Mental HealthParkvilleAustralia
  2. 2.Melbourne Brain Centre at The Royal Melbourne Hospital, The Department of MedicineThe University of MelbourneParkvilleAustralia
  3. 3.Academic Centre, Ormond CollegeParkvilleAustralia
  4. 4.Department of Medicine, The Royal Melbourne HospitalThe University of MelbourneParkvilleAustralia
  5. 5.Department of NeurologySt Vincent’s Hospital MelbourneFitzroyAustralia
  6. 6.Department of Neurology, Western HealthSunshineAustralia
  7. 7.Department of Medical EducationThe University of MelbourneParkvilleAustralia
  8. 8.St Vincent’s Hospital Library ServiceSt Vincent’s Hospital MelbourneFitzroyAustralia
  9. 9.Bone and Mineral Medicine, The Royal Melbourne HospitalParkvilleAustralia

Personalised recommendations